Cell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis

Abstract Background Lymphedema, the accumulation of interstitial fluid caused by poor lymphatic drainage, is a progressive and permanent disease with no curative treatment. Several studies have evaluated cell-based therapies in secondary lymphedema, but no meta-analysis has been performed to assess...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hector Lafuente, Ibon Jaunarena, Eukene Ansuategui, Arantza Lekuona, Ander Izeta
Formato: article
Lenguaje:EN
Publicado: BMC 2021
Materias:
Acceso en línea:https://doaj.org/article/ce46e23cc8824a7db5073ff465a6cd69
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:ce46e23cc8824a7db5073ff465a6cd69
record_format dspace
spelling oai:doaj.org-article:ce46e23cc8824a7db5073ff465a6cd692021-11-21T12:04:44ZCell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis10.1186/s13287-021-02632-y1757-6512https://doaj.org/article/ce46e23cc8824a7db5073ff465a6cd692021-11-01T00:00:00Zhttps://doi.org/10.1186/s13287-021-02632-yhttps://doaj.org/toc/1757-6512Abstract Background Lymphedema, the accumulation of interstitial fluid caused by poor lymphatic drainage, is a progressive and permanent disease with no curative treatment. Several studies have evaluated cell-based therapies in secondary lymphedema, but no meta-analysis has been performed to assess their efficacy. Methods We conducted a systematic review and meta-analysis of all available preclinical and clinical studies, with assessment of their quality and risk of bias. Results A total of 20 articles using diverse cell types were selected for analysis, including six clinical trials and 14 pre-clinical studies in three species. The meta-analysis showed a positive effect of cell-based therapies on relevant disease outcomes (quantification of edema, density of lymphatic capillaries, evaluation of the lymphatic flow, and tissue fibrosis). No significant publication bias was observed. Conclusion Cell-based therapies have the potential to improve secondary lymphedema. The underlying mechanisms remain unclear. Due to relevant heterogeneity between studies, further randomized controlled and blinded studies are required to substantiate the use of these novel therapies in clinical practice.Hector LafuenteIbon JaunarenaEukene AnsuateguiArantza LekuonaAnder IzetaBMCarticleStem cellsLymphatic vasculatureLymphedemaRegenerationRegenerative medicineSystematic reviewMedicine (General)R5-920BiochemistryQD415-436ENStem Cell Research & Therapy, Vol 12, Iss 1, Pp 1-17 (2021)
institution DOAJ
collection DOAJ
language EN
topic Stem cells
Lymphatic vasculature
Lymphedema
Regeneration
Regenerative medicine
Systematic review
Medicine (General)
R5-920
Biochemistry
QD415-436
spellingShingle Stem cells
Lymphatic vasculature
Lymphedema
Regeneration
Regenerative medicine
Systematic review
Medicine (General)
R5-920
Biochemistry
QD415-436
Hector Lafuente
Ibon Jaunarena
Eukene Ansuategui
Arantza Lekuona
Ander Izeta
Cell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis
description Abstract Background Lymphedema, the accumulation of interstitial fluid caused by poor lymphatic drainage, is a progressive and permanent disease with no curative treatment. Several studies have evaluated cell-based therapies in secondary lymphedema, but no meta-analysis has been performed to assess their efficacy. Methods We conducted a systematic review and meta-analysis of all available preclinical and clinical studies, with assessment of their quality and risk of bias. Results A total of 20 articles using diverse cell types were selected for analysis, including six clinical trials and 14 pre-clinical studies in three species. The meta-analysis showed a positive effect of cell-based therapies on relevant disease outcomes (quantification of edema, density of lymphatic capillaries, evaluation of the lymphatic flow, and tissue fibrosis). No significant publication bias was observed. Conclusion Cell-based therapies have the potential to improve secondary lymphedema. The underlying mechanisms remain unclear. Due to relevant heterogeneity between studies, further randomized controlled and blinded studies are required to substantiate the use of these novel therapies in clinical practice.
format article
author Hector Lafuente
Ibon Jaunarena
Eukene Ansuategui
Arantza Lekuona
Ander Izeta
author_facet Hector Lafuente
Ibon Jaunarena
Eukene Ansuategui
Arantza Lekuona
Ander Izeta
author_sort Hector Lafuente
title Cell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis
title_short Cell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis
title_full Cell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis
title_fullStr Cell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis
title_full_unstemmed Cell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis
title_sort cell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis
publisher BMC
publishDate 2021
url https://doaj.org/article/ce46e23cc8824a7db5073ff465a6cd69
work_keys_str_mv AT hectorlafuente celltherapyasatreatmentofsecondarylymphedemaasystematicreviewandmetaanalysis
AT ibonjaunarena celltherapyasatreatmentofsecondarylymphedemaasystematicreviewandmetaanalysis
AT eukeneansuategui celltherapyasatreatmentofsecondarylymphedemaasystematicreviewandmetaanalysis
AT arantzalekuona celltherapyasatreatmentofsecondarylymphedemaasystematicreviewandmetaanalysis
AT anderizeta celltherapyasatreatmentofsecondarylymphedemaasystematicreviewandmetaanalysis
_version_ 1718419271497809920